कंपनी का अवलोकन
ASP Isotopes Inc. operates as a development-stage advanced materials company dedicated to the production, distribution, marketing, and sale of isotopes across its specialized segments. The firm functions within the Basic Materials sector, specifically the Chemicals industry, a classification that underscores its focus on essential industrial compounds and nuclear fuel research. This enterprise employs a workforce of 136 individuals to support its operational infrastructure while maintaining a total market capitalization of $526.71M. The company generated annual revenue of $8.38M over the trailing twelve-month period, a figure that places it in a small-cap category relative to large industrial peers. These valuation metrics and revenue scales indicate that ASP Isotopes Inc. is currently a niche player with limited market penetration, reflecting the high-risk, high-potential nature typical of development-stage entities in the isotopes market.
वित्तीय स्वास्थ्य
The company reported a revenue of $8.38M for the trailing twelve months, yet this top-line figure contrasts sharply with a net income of $-105,564,392, revealing a severe structural cost burden where expenses vastly exceed earnings before interest and taxes. EBITDA stands at $-41,514,560, further confirming that the business model is currently operating at a significant operational loss rather than generating operational profit. Free cash flow is recorded at $-67,549,232, indicating that the company is burning cash reserves to fund its development activities without generating sufficient internal liquidity to sustain operations independently. Gross margin sits at 23.0%, suggesting that production costs consume the majority of revenue, while the operating margin of -306.1% and profit margin of 0.0% highlight extreme operational inefficiencies or heavy capital expenditure requirements relative to sales. Despite these losses, the firm holds $114.04M in cash against $113.66M in debt, resulting in a debt-to-equity ratio of 117.65, which signals an extremely leveraged balance sheet where liabilities nearly match liquid assets. The current ratio of 6.14 suggests strong short-term liquidity relative to current liabilities, providing a buffer despite the negative earnings trajectory. Return on Equity is -152.6% and Return on Assets is -17.2%, metrics that demonstrate management is currently destroying value per share and utilizing assets inefficiently to generate positive returns.
मूल्यांकन आकलन
Trailing P/E Ratio (TTM) is listed as N/A due to the absence of positive earnings, while the forward P/E is -5.85, a negative figure that implies the market is pricing in expected future losses or a lack of near-term profitability. The price-to-book ratio stands at 5.31, indicating that the market values the company at more than five times its net asset value, which may reflect optimism regarding future isotopes demand or asset revaluation potential. Price-to-sales is 62.83 and EV/EBITDA is -11.77, alternative metrics that suggest the valuation is driven entirely by revenue multiples rather than earnings power, often seen in pre-profitability biotech or materials firms. The stock trades between a 52-week high of $14.49 and a 52-week low of $3.92, establishing a wide volatility range that reflects the speculative nature of the security. The beta of 3.61 indicates that the stock price is significantly more volatile than the broader market, moving with three and a half times the intensity of general market swings during periods of fluctuation.
Growth & Income
Revenue growth year-over-year is an extraordinary 349.5%, driven by recent sales increases, while earnings growth is N/A due to the company's current unprofitability and negative net income history. Because the company has not generated positive earnings, there is no sustainable earnings growth trajectory to compare against revenue expansion, highlighting the risk that top-line growth does not yet translate to bottom-line profitability. As a non-dividend payer, ASP Isotopes Inc. reports a dividend yield of N/A and a payout ratio of 0.0%, meaning the firm retains all generated cash to fund its capital-intensive research and development efforts rather than distributing income to shareholders. The overall growth and income profile is characterized by explosive revenue expansion paired with substantial cash burn and a complete absence of dividend income, creating a high-risk, high-reward scenario dependent on future operational turnaround.